M.D., Ph.D., VP, Clinical Development, Intellia Therapeutics
Biography
Mark McKee, M.D leads the medical sciences group within Clinical Development at Intellia therapeutics. In addition, he has served as the head of program teams for several of Intellia’s lead assets during his tenure at the company. Prior to joining Intellia, Mark was in the Oncology Clinical Development group at AbbVie and was a physician and researcher at the University of Chicago. He received his Bachelor of Science and Medical Degrees from Northwestern University and completed his clinical training at Harvard Beth Israel Deaconess medical Center and the National Institutes of Health.
Session Abstract – PMWC 2022 Silicon Valley
Track 1 - June 30 9.15 A.M.-10.15 P.M.
Panel
Session Abstract – PMWC 2022 Silicon Valley
Track 1 - June 30 9.15 A.M.-10.15 P.M.
Track Chair:
Vanessa Soros, Graphite Bio
Sessions:
- Gene & Cell Therapies Overview
- Janice Chen, Mammoth
- Cutting Edge Technologies for Gene Engineering and Cell Therapy (PANEL)
Session Chair: Vanessa Soros, Graphite Bio
- Mark McKee, Intellia Tx
- Amy Simon, Beam Therapeutics
- Eric Ostertag, Poseida Therapuetics
- Translating CGT to the Clinic (PANEL)
Session Chair: Nicole K. Paulk, UCSF
- Matthew Porteus, Stanford
- Peter Francis, 4D Molecular Therapeutics
- Erandi De Silva, Forge Biologics
- Patrice Hugo, Q2 Solutions
- Susanne Fors, Ultragenyx - PMWC Showcase
- Yuri Fesko, Labcorp
- Yan Zhang, Mission Bio
- Anil Narasimha, Mekonos Inc.
- Emily Anderson, Horizon, a PerkinElmer Company
- Jesse Salk, Twinstrand
- William Shrader, AcureX Therapeutics - Emerging Gene Therapies for Epidermolysis Bullosa
- Peter Marinkovich, Stanford - Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential (PANEL)
Session Chair: Janice Chen, Mammoth
- Kiana Aran, Cardea Bio
- Mark McKee, Intellia Tx
- Josh Lehrer, Graphite Bio
Session Abstract – PMWC 2022 Silicon Valley
Track 1 - June 30 3.30 P.M.-4.30 P.M.
The last 10 years have been a breakout decade for CRISPR across research and medicine, and the next decade holds the potential for CRISPR to cure the underlying cause of genetic disease. This session will discuss the latest breakthroughs in the field and address the challenges that need to be overcome to deliver on the promise of CRISPR.
